Israel’s Teva is partnering with the Technion for research into new immunotherapy methods to treat cancer and nervous system diseases.

Kåre Schultz, former chief executive at H. Lundbeck A/S, to steer Israeli drugmaker to divest assets, cut debt and restore investor confidence

February 7, 2017 | Teva Pharmaceutical Industries Ltd. announced last night that CEO Erez Vigodman has resigned. He will be replaced as interim president and CEO by Dr. Yitzhak Peterburg, who has served as Chairman of the Teva Board of Directors since January 2015. Vigodman’s sudden departure is unexpected but not entirely surprising. The world’s largest generic […]